Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations; presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the FDA acceptable intake limit.
| Brand name | DULOXETINE |
| Generic name | DULOXETINE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Asclemed USA Inc. |
| NDC | 76420-634-30 |
| Full product label | Duloxetine DR Capsules, 30 mg, 30 count bottles, Rx, Relabeled by: Enovachem Pharmaceuticals, Torrance, CA 90501, NDC 76420-634-30, Marketed by: Ajanta Pharma USA Inc. |
| Recalling firm | Asclemed USA Inc. |
| Distribution | US Nationwide. |
| Quantity | 50 bottles |
| Recall initiated | 2026-05-14 |
| Report date | 2026-06-10 |
| Recall completed | — |
| Recall number | D-0555-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Torrance CA United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗